+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Relapsing Remitting Multiple Sclerosis (RRMS) Global Clinical Trials Review, H1, 2018

  • ID: 4614634
  • Clinical Trials
  • June 2018
  • Region: Global
  • 446 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Bayer AG
  • Biogen Inc
  • E. Merck KG
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • MORE
Relapsing Remitting Multiple Sclerosis (RRMS) Global Clinical Trials Review, H1, 2018

Summary

The author's clinical trial report, “Relapsing Remitting Multiple Sclerosis (RRMS) Global Clinical Trials Review, H1, 2018" provides an overview of Relapsing Remitting Multiple Sclerosis (RRMS) clinical trials scenario. This report provides top line data relating to the clinical trials on Relapsing Remitting Multiple Sclerosis (RRMS). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using the author's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Bayer AG
  • Biogen Inc
  • E. Merck KG
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • MORE
Report Guidance
Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Relapsing Remitting Multiple Sclerosis (RRMS) to Central Nervous System Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Relapsing Remitting Multiple Sclerosis (RRMS) to Central Nervous System Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Relapsing Remitting Multiple Sclerosis (RRMS)
Jun 18, 2018: Data Provide Further Insight Into the Consistent Efficacy Benefits of Mavenclad in Relapsing MS
Apr 23, 2018: Treatment Effects Maintained over Seven Years in Patients with Relapsing Remitting Multiple Sclerosis Who Received Lemtrada (alemtuzumab) in Clinical Trials
Apr 21, 2018: Mylan Presents Equivalence Data on Glatiramer Acetate Compared to Copaxone at American Academy of Neurology 70th Annual Meeting
Apr 19, 2018: Sanofi Genzyme’s Multiple Sclerosis Data to Be Featured at AAN
Apr 17, 2018: Teva to Present New Data on COPAXONE at 70th Annual Meeting of the American Academy of Neurology
Apr 13, 2018: EMD Serono Highlights Commitment to Advance Multiple Sclerosis Treatment with Investigational Cladribine Tablets
Apr 13, 2018: EMD Serono Highlights Commitment to Advance Multiple Sclerosis Treatment with Investigational Rebif Data at AAN 2018
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About
Contact
Source

List of Tables
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials by Region, 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, North America, Top Countries, 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018*
Proportion of Relapsing Remitting Multiple Sclerosis (RRMS) to Central Nervous System Clinical Trials, G7 Countries (%), 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
Proportion of Relapsing Remitting Multiple Sclerosis (RRMS) to Central Nervous System Clinical Trials, E7 Countries (%), 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials by Phase, 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials In Progress by Phase 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials by Trial Status, 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, by End Point Status, 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*

List of Figures
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials by Region (%), 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, North America, Top Countries (%), 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018*
Proportion of Relapsing Remitting Multiple Sclerosis (RRMS) to Central Nervous System Clinical Trials, G7 Countries (%), 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
Proportion of Relapsing Remitting Multiple Sclerosis (RRMS) to Central Nervous System Clinical Trials, E7 Countries (%), 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials by Phase (%), 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials by Trial Status, 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, by End Point Status, 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*
Methodology
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Biogen Inc
  • Novartis AG
  • Sanofi
  • Teva Pharmaceutical Industries Ltd
  • Bayer AG
  • E. Merck KG
  • GlaxoSmithKline Plc
  • F. Hoffmann-La Roche Ltd
  • AbbVie Inc
  • Johnson & Johnson
Note: Product cover images may vary from those shown
Adroll
adroll